XM does not provide services to residents of the United States of America.
E
E

EastmanChemical

News

Eastman Chemical Co Expects $800 Million Capital Expenditures In 2025

BRIEF-Eastman Chemical Co Expects $800 Million Capital Expenditures In 2025 Nov 21 (Reuters) - Eastman Chemical Co EMN.N : EASTMAN CHEMICAL CO - EXPECTS $800 MILLION CAPITAL EXPENDITURES IN 2025 Source text: [t.ly/9FK8H] Further company coverage: EMN.N
E

U.S. Apollo, Booking Holdings, Portillos

U.S. RESEARCH ROUNDUP-Apollo, Booking Holdings, Portillos Nov 6 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apollo, Booking Holdings and Portillos, on Wednesday. HIGHLIGHTS * Apollo APO.N : JP Morgan raises target price to $161 from $143 * Aris Water Solutions Inc ARIS.N : JP Morgan cuts to neutral from overweight * Booking Holdings Inc BKNG.O : Truist Securities raises target to $4,700 from $4,100 * Choice Hotel
A
E
M
C
F
X
B
C
C
E
G
L

Eastman Chemical Co reports results for the quarter ended in September 30 - Earnings Summary

Eastman Chemical Co reports results for the quarter ended in September 30 - Earnings Summary Eastman Chemical Co EMN.N reported quarterly adjusted earnings of $2.26​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $1.47. The mean expectation of nineteen analysts for the quarter was for earnings of $2.14 per share.
E

Eastman Chemical beats Q3 profit estimates on higher sales

Eastman Chemical beats Q3 profit estimates on higher sales Oct 31 (Reuters) - Eastman Chemical EMN.N beat Wall Street estimates for third-quarter profit on Thursday, driven by higher revenues amid a pickup in global manufacturing activity and an end to destocking, while also tightening its full-year earnings outlook. The company, however, flagged that due to normal seasonal volume declines across key end markets, fourth-quarter earnings before interest and taxes could be lower than those of the
E

Eastman Chemical Q3 Adjusted EPS USD 2.26 Vs. IBES Estimate USD 2.14

BRIEF-Eastman Chemical Q3 Adjusted EPS USD 2.26 Vs. IBES Estimate USD 2.14 Oct 31 (Reuters) - Eastman Chemical Q3 EPS USD 1.53. Q3 adjusted EBIT USD 366 million vs. IBES estimate USD 347.7 million Q3 EBIT USD 329 million Q3 revenue USD 2,464 million vs. IBES estimate USD 2,378 million outlook FY EPS USD 7.5-7.7
E

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.